These 4 Measures Indicate That Gilead Sciences (NASDAQ:GILD) Is Using Debt Reasonably Well
Nov 17
U.S. Biotech Industry Analysis
UpdatedDec 06, 2023
DataAggregated Company Financials
Companies670
- 7D4.1%
- 3M0.6%
- 1Y-4.8%
- YTD-4.2%
Over the last 7 days, the Biotech industry has risen 4.1%, driven by gains from AbbVie of 4.7%. Meanwhile, Arrowhead Pharmaceuticals actually underperformed within the industry, shrinking 19% in the last week. However, the industry is down 4.8% over the past year. Looking forward, earnings are forecast to grow by 20% annually.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 06 Dec 2023 | US$1.3t | US$204.6b | -US$22,051,652,521.00 | 19.3x | -57.6x | 6.2x |
| Fri, 03 Nov 2023 | US$1.2t | US$206.8b | -US$20,351,431,827.00 | 17.2x | -59.7x | 5.9x |
| Sun, 01 Oct 2023 | US$1.3t | US$207.4b | -US$13,122,605,528.00 | 17.1x | -95.8x | 6.1x |
| Tue, 29 Aug 2023 | US$1.3t | US$207.6b | -US$12,455,656,838.00 | 17.5x | -102.5x | 6.1x |
| Thu, 27 Jul 2023 | US$1.1t | US$186.8b | -US$16,232,873,446.00 | 14.3x | -69.8x | 6.1x |
| Sat, 24 Jun 2023 | US$1.1t | US$186.2b | -US$16,162,116,001.00 | 13.6x | -70.3x | 6.1x |
| Mon, 22 May 2023 | US$1.2t | US$186.0b | -US$15,898,792,960.00 | 13x | -72.5x | 6.2x |
| Wed, 19 Apr 2023 | US$1.2t | US$198.4b | -US$3,275,992,798.00 | 13.4x | -358.6x | 5.9x |
| Fri, 17 Mar 2023 | US$1.1t | US$199.1b | -US$4,760,446,272.00 | 13.3x | -238.2x | 5.7x |
| Sun, 12 Feb 2023 | US$1.2t | US$202.7b | -US$201,937,721.00 | 16.4x | -5723.2x | 5.7x |
| Tue, 10 Jan 2023 | US$1.1t | US$203.5b | US$1.7b | 13.8x | 685.5x | 5.6x |
| Thu, 08 Dec 2022 | US$1.2t | US$202.6b | US$1.4b | 14.9x | 839.9x | 5.7x |
| Sat, 05 Nov 2022 | US$1.1t | US$204.6b | US$3.6b | 14.2x | 299.5x | 5.3x |
| Mon, 03 Oct 2022 | US$1.0t | US$206.2b | US$5.5b | 14.9x | 187.1x | 4.9x |
| Wed, 31 Aug 2022 | US$1.0t | US$206.3b | US$7.3b | 14.4x | 141.1x | 5x |
| Fri, 29 Jul 2022 | US$1.1t | US$211.2b | US$11.2b | 16.4x | 96.6x | 5.1x |
| Sun, 26 Jun 2022 | US$1.1t | US$212.4b | US$11.1b | 15.4x | 95.1x | 4.9x |
| Tue, 24 May 2022 | US$1.0t | US$212.6b | US$11.1b | 14.9x | 90.9x | 4.7x |
| Thu, 21 Apr 2022 | US$1.2t | US$226.7b | US$14.8b | 18.1x | 84.2x | 5.5x |
| Sat, 19 Mar 2022 | US$1.3t | US$222.3b | US$10.5b | 19.8x | 123.5x | 5.8x |
| Mon, 14 Feb 2022 | US$1.3t | US$216.3b | US$6.0b | 21.8x | 209.6x | 5.8x |
| Wed, 12 Jan 2022 | US$1.4t | US$212.1b | US$2.7b | 24.7x | 501.5x | 6.4x |
| Fri, 10 Dec 2021 | US$1.4t | US$211.9b | US$3.0b | 25x | 464.4x | 6.7x |
| Sun, 07 Nov 2021 | US$1.5t | US$204.6b | US$1.1b | 27.3x | 1366x | 7.2x |
| Tue, 05 Oct 2021 | US$1.5t | US$196.3b | -US$2,477,112,279.00 | 24.4x | -592.9x | 7.5x |
| Thu, 02 Sep 2021 | US$1.6t | US$197.0b | -US$1,737,879,785.58 | 22.3x | -928.4x | 8.2x |
| Sat, 31 Jul 2021 | US$1.5t | US$197.0b | -US$1,459,590,878.58 | 24.2x | -1036.4x | 7.7x |
| Tue, 04 May 2021 | US$1.4t | US$174.8b | -US$11,096,405,382.55 | 22.2x | -127.4x | 8.1x |
| Fri, 05 Feb 2021 | US$1.4t | US$162.7b | -US$10,894,429,089.90 | 19x | -128.8x | 8.6x |
Price to Earnings Ratio
-121.1x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.4x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have deteriorated over the last three years.
- Meanwhile revenues for these companies have grown 8.0% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.56% | |
| Healthcare | 2.01% | |
| Biotech | 4.13% | |
| Biotech | 4.13% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$144.57 | 4.7% +US$11.5b | -11.7% | PE39.4x | |
| GILD Gilead Sciences | US$79.02 | 6.1% +US$5.6b | -10.2% | PE16.8x | |
| IMGN ImmunoGen | US$29.21 | 82.8% +US$3.6b | 451.1% | PS27.2x | |
| AMGN Amgen | US$270.87 | 2.0% +US$2.9b | -4.4% | PE19.2x | |
| REGN Regeneron Pharmaceuticals | US$820.90 | 2.5% +US$2.1b | 9.8% | PE21.9x |